Perfromance Wealth Partners LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Perfromance Wealth Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 735 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.

Several other large investors have also recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. increased its position in shares of Alnylam Pharmaceuticals by 34.3% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 1,164 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 297 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 15.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,917 shares of the biopharmaceutical company’s stock valued at $1,277,000 after purchasing an additional 522 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Alnylam Pharmaceuticals by 15.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 312,216 shares of the biopharmaceutical company’s stock valued at $100,552,000 after purchasing an additional 41,292 shares during the last quarter. OFI Invest Asset Management increased its position in shares of Alnylam Pharmaceuticals by 26.2% during the 2nd quarter. OFI Invest Asset Management now owns 381 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 79 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its position in Alnylam Pharmaceuticals by 47.3% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,390 shares of the biopharmaceutical company’s stock valued at $4,368,000 after acquiring an additional 4,302 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $464.95 on Tuesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The stock has a market capitalization of $60.95 billion, a price-to-earnings ratio of -188.24 and a beta of 0.36. The stock has a fifty day simple moving average of $452.27 and a two-hundred day simple moving average of $347.50. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the prior year, the business earned ($0.13) EPS. The business’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on ALNY shares. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 price objective on the stock. Citigroup upped their price objective on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Piper Sandler upped their price objective on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. UBS Group upped their price objective on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Twenty-four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $457.08.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 3,022 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the sale, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,103,454.05. Following the sale, the executive vice president owned 25,231 shares of the company’s stock, valued at $11,405,673.55. This trade represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,144 shares of company stock worth $44,160,261. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.